At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 13, 2026 at 16:29 ET
Spyre Therapeutics reported preliminary cash of $741M as of March 31, 2026, including $30M from legacy asset sales, while terminating its ATM offering. The cash update is positive, but halting equity financing suggests caution despite strong liquidity.
- Company expects ~$741M in cash, cash equivalents, and marketable securities as of March 31, 2026
- Cash includes $30M from legacy asset disposition, $23M of which is expected to be paid to CVR holders in Q2 2026
- Terminated at-the-market (ATM) prospectus, halting common stock sales under the existing agreement
- Sales Agreement with TD Securities remains in effect; new prospectus would be needed to restart sales
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access